SISRAM MED (01696) achieved a double-digit year-on-year growth in unaudited revenue in the third quarter and will steadily advance the commercialization process of Daxifay in the mainland.

SISRAM MED(01696) announced that the group's new orders in the third quarter of 2025 maintained strong growth momentum, mainly benefiting from the performance in the Chinese, Korean, and Thai markets. The flagship multifunctional device, Alma Harmony, achieved steady growth this quarter. As a result, the group's unaudited revenue for this quarter achieved a double-digit year-on-year growth. With continuous market expansion and demand exploration, the group will further promote the penetration of the Soprano series in the Asia-Pacific region within the year, and fully promote the commercial deployment of Universkin by Alma in the US market. At the same time, the commercialization process of Daxi Fei in mainland China will be orderly promoted as planned.